![Stephen Biggar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Biggar
Presidente en ACADIA PHARMACEUTICALS INC. .
Fortuna: 93 350 $ al 30/06/2024
Cargos activos de Stephen Biggar
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ACADIA PHARMACEUTICALS INC. | Independent Dir/Board Member | 22/01/2013 | - |
Presidente | 10/06/2016 | - | |
Director/Miembro de la Junta | 22/01/2013 | 10/06/2016 | |
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Director/Miembro de la Junta | 01/10/2015 | - |
Independent Dir/Board Member | 01/10/2015 | - | |
TSCAN THERAPEUTICS, INC. | Independent Dir/Board Member | 01/03/2021 | - |
Presidente | 12/06/2024 | - | |
Director/Miembro de la Junta | 01/03/2021 | 12/06/2024 | |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | - | - |
Historial de carrera de Stephen Biggar
Antiguos cargos conocidos de Stephen Biggar.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SYNAGEVA BIOPHARMA CORP | Director/Miembro de la Junta | 02/11/2011 | 22/06/2015 |
Independent Dir/Board Member | 02/11/2011 | 22/06/2015 | |
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Director/Miembro de la Junta | - | 04/11/2011 |
BIOCRYST PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 03/10/2005 | 10/10/2011 |
Vivelix Pharmaceuticals, Ltd.
![]() Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Director/Miembro de la Junta | - | - |
Baker Bros. Advisors LP
![]() Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Gestor de Cartera-Acciones | 01/04/2000 | - |
Corporate Officer/Principal | 01/04/2000 | - |
Formación de Stephen Biggar.
Stanford University | Doctorate Degree |
Rochester Christian University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 10 |
Bermudas | 2 |
Canadá | 2 |
Operativa
Director/Board Member | 10 |
Independent Dir/Board Member | 4 |
Chairman | 2 |
Sectorial
Health Technology | 9 |
Consumer Services | 3 |
Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
ACADIA PHARMACEUTICALS INC. | Health Technology |
TSCAN THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Baker Bros. Advisors LP
![]() Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Kiniksa Pharmaceuticals Ltd.
![]() Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
Vivelix Pharmaceuticals, Ltd.
![]() Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Health Technology |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Stephen Biggar
- Experiencia